In the Latin language SPERA means Hope. Our newly developed subtle pulse device delivers hope of recovery from a broad range of health issues including drug dependency, traumatic stress and chronic pain. These complex conditions are electro-biological in nature and require a neurological solution. This recovery apparatus applies an evidence-based approach, which has been well established in scientific research and medical practice for over 100 years. Remedies have become widely available to manage human suffering but SPERA is unique in its offer of relief from pain, stress and dependency with limited or no requirement for harmful medication. Take a look out our Case Studies section for examples of how SPERA is already being used to free people from their dependencies or years of chronic illness.

In 1914 a distinguished Dutch-American Physicist patented a portable electro-anaesthesia device for use in dental surgery. His apparatus was based on an advanced understanding of electrical frequencies, wavelengths and wave-shapes. While chemical anaesthesiology has become much more familiar during the last century the use of subtle-pulse pain and stress relief has also been developed to a very high standard. Not only can this approach provide calming relief during surgery, it also provides drug-free analgesia, which in turn leads to a swifter recovery. Diverse examples of this are well known, thoroughly researched and widely applied in China, France, Russia and the USA.

During the mid-1970s various practitioners were successful in developing this science through the use of emerging computer technology and state-of-the-art electronic components. The safety, effectiveness and range of treatments increased, using micro currents and frequencies similar to those generated naturally by the brain. In scientific publications this intervention was variously defined as TCES (trans-cranial electro stimulation), CES (cerebral-electro-stimulation) and NET (neuro-electric stimulation). Some researchers achieved notable breakthroughs in the relief of acute and chronic suffering. A few mass-produced applications became available to medical practitioners, surgeons and the general public.

Despite numerous patents, research publications, and media reports over the past century the availability of subtle-pulse devices for the relief of dependencies, pain and stress have been limited in scale and scope. Neither have scientists and practitioners benefited from the comprehensive open-sourcing of treatment parameters or access to generic technology for global on-going research and development. Huge numbers of people could benefit from this knowledge, but are currently unaware that a proven drug-free solution exists, not least poly-drug users unable to escape their addictions. It has been demonstrated that properly applied subtle pulses can enable withdrawal from dependencies in a few days without cravings. Neither are there any negative side-effects. Moreover, this treatment acts by stimulating the normal neuro-chemical balance in the brain and strengthening or restoring the body’s natural immune system.

It is often asked, ‘If such a successful, painless, holistic and proven treatment exists – why is it not readily available?’ Others who understand this science have suggested, ‘couldn’t such a technology provide non-invasive solutions for a range of chronic sicknesses which arise from deficits in the brain or immune system?’ In professional consultations it has been imagined, ‘such an approach would be an elegant, safe, inexpensive option, easily used in any home, medical, or residential setting. There are multiple reasons to explain why portable subtle-pulse electronic devices are not on the supermarket or pharmacy shelves. Conspiracy theories are easy to imagine, one could speculate that corporations want to protect their markets, that developers don’t want potential rivals to steal their intellectual property, or that researchers want to conceal their discoveries until prizes are awarded. As with any significant advance in knowledge, human greed has a lot to answer for. Previous devices that could have radically transformed the scale and scope of relief from suffering have been buried in laboratories, buried in spent patents, or buried in scientific archives.

Ten years ago Dr Graham Giles became the primary advisor to the Romanian National Anti-drug Agency (ANA) and joined the International Council on Alcohol and Addictions (ICAA). At that time Graham traveled to California and Mexico to receive two devices that could treat nicotine and alcohol dependency. These had been the legacy of a distinguished Scottish surgeon. Later her family permitted Graham to conduct missions of mercy and clinical trials with another 17 devices, which had programmed prescriptions for the detoxification of all commonly used drugs. Ultimately, official trials were conducted in Scotland, Romania and Eastern Kentucky with completely replicated outcomes. At the invitation of the Kentucky River Area Development District (KRADD) Graham received the most challenging male and female groups of adults with multiple drug and alcohol addictions. These successful interventions demonstrated that different subtle-pulse prescriptions could relieve all beneficiaries from their withdrawal symptoms and long-term cravings. We enjoyed near 100% retention in treatment and an extremely low recidivism level with minimal follow-up.

For over five years, access to that legacy device has been restricted to closed trials. It is not anticipated that further such treatments or clinical trials will be permitted in the near future. Indeed the existing treatment options have seen no further development for twenty years and offer no prospect of prescriptions for other neurological conditions.

Therefore, Graham was encouraged to extend a meta-analysis of published research, a century of spent patents and on his own observations from using various available devices. With the support of a British medical device manufacturer and electronics engineers it became feasible to design a new motherboard and unique prescription software.

During this time a retired scientist who pioneered this technology for many years and gained international distinction in the field joined our team. SPERA currently contains seven day treatment prescriptions for poly-drug detoxification and a range of ailments including the relief of chronic pain, allergies and eating disorders. Our intention is to field test our generic apparatus, publish our conclusions and make our pulse-parameters openly available to other researchers. We will then scale up clinical trials to develop national projects for designing standard treatment systems for drug detoxification and the relief of chronic ailments.

Within Grahams ‘Highways of Health’ initiative we plan to create a Social Enterprise to market devices with treatments for specific conditions. These will include nicotine and alcohol detoxification, relief of pain, eating disorders, post-traumatic stress and panic attacks. Resources from marketed single treatment instruments would then be devoted to reopening scientific exploration of unfinished applications. It is proposed to conduct future research and development in a world-class British University with all our efforts devoted to greatly increase the scale and scope of subtle-pulse technologies for beneficiaries, practitioners and scientists.